Epizyme (EPZM) Tops Q4 EPS by 12c

Epizyme (NASDAQ: EPZM) reported Q4 EPS of ($0.53), $0.12 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $555 thousand versus the consensus estimate of $570 thousand.

Based on these significant advancements throughout 2015, Epizyme has outlined a vision and strategic plan through 2020, focused on quickly bringing tazemetostat to market, maximizing the potential of tazemetostat in a broad range of cancers and treatment settings, continuing the growth of its pipeline and further establishing the company’s scientific leadership in the field of chromatin modifying proteins. More details on the vision and strategy can be found here.

For earnings history and earnings-related data on Epizyme (EPZM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c